Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · March 10, 2022

Efficacy of Biosimilar HD201 vs Referent Trastuzumab in ERBB2+ Breast Cancer Treated in the Neoadjuvant Setting

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
JAMA Oncol 2022 Mar 03;[EPub Ahead of Print], X Pivot, MA Georgievich, V Shamrai, G Dzagnidze, H Fen, V Kaewkangsadan, F Petrelli, C Villanueva, LO Nikolaevich, J Hii, J Kim, S Pradhan, L Jaison, P Feyaerts, L Kaufman, MP Derde, GMC Bonamy, F Deforce, DG Cox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading